Characteristics of patients starting adalimumab treatment (n=272)
| Baseline variables | |
| Female, n (%) | 219 (81) |
| Rheumatoid factor, n (%) | 195 (72) |
| Age, mean (SD) | 54 (12) |
| Erosive disease, n (%) | 201 (74) |
| Methotrexate use, n (%) | 202 (74) |
| Prednisone use, n (%) | 91 (34) |
| Prior biological use, n (%) | 75 (28) |
| DAS28, mean (SD) | 5.2 (1.2) |
| HAQ, mean (SD) | 1.32 (0.68) |
| Utility, mean (SD) | 0.59 (0.15) |
| 6 months follow-up | |
| Adalimumab concentration, mg/L (IQR) | |
| Total population | 10 (4.6–14.8) |
| Responders | 10.9 (6.2–15.7) |
| Non-responders | 7.4 (1.5–11.9) |